If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Forteo ® (teriparatide [rDNA origin] injection)
20-mcg daily dose in a 2.4-mL prefilled delivery device
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
FORTEO® (teriparatide [rDNA origin] injection): Mechanism of Action
Once-daily administration of Forteo preferentially stimulates osteoblastic activity over osteoclastic activity, resulting in new bone formation.
Once-daily administration of teriparatide preferentially stimulates osteoblastic activity over osteoclastic activity, resulting in new bone formation.1
New bone formation is observed on the trabecular and cortical (periosteal and/or endosteal) bone surfaces.1
Structural histomorphometric analyses conducted on iliac crest biopsies from PMW with osteoporosis revealed that teriparatide improved
trabecular bone volume
trabecular bone connectivity
structure model index, and
cortical thickness.2
Dynamic histomorphometric analyses conducted on iliac crest biopsies from PMW with osteoporosis demonstrated that teriparatide stimulates bone formation on all bone envelopes (cancellous, endocortical, intracortical, and periosteal) as early as 3 months and remains sustained for the full 24 months of therapy.3,4
Radionuclide bone scan imaging has demonstrated a direct metabolic effect of teriparatide on the whole skeleton and various subskeletal sites.5
New bone formed during teriparatide treatment has lower, more heterogeneous, mineral content, a property consistent with younger bone age.6
Enclosed Prescribing Information
FORTEO® (teriparatide [rDNA origin] injection), Lilly
References
The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).
1. Forteo [package insert]. Indianapolis IN: Eli Lilly and Company; 2019.
2. Jiang Y, Zhao JJ, Mitlak BH, et al. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res. 2003;18(11):1932-1941. https://doi.org/10.1359/jbmr.2003.18.11.1932
3. Dempster DW, Zhou H, Recker RR, et al. A longitudinal study of skeletal histomorphometry at 6 and 24 months across four bone envelopes in postmenopausal women with osteoporosis receiving teriparatide or zoledronic acid in the SHOTZ trial. J Bone Miner Res. 2016;31(7):1429-1439. http://dx.doi.org/10.1002/jbmr.2804
4. Dempster DW, Zhou H, Recker RR, et al. Differential effects of teriparatide and denosumab on intact PTH and bone formation indices: AVA osteoporosis study. J Clin Endocrinol Metab. 2016;101(4):1353-1363. http://dx.doi.org/10.1210/jc.2015-4181
5. Moore AE, Blake GM, Taylor KA, et al. Changes observed in radionuclide bone scans during and after teriparatide treatment for osteoporosis. Eur J Nucl Med Mol Imaging. 2012;39(2):326-336 http://dx.doi.org/10.1007/s00259-011-1974-y
6. Dempster DW, Roschger P, Misof BM, et al. Differential effects of teriparatide and zoledronic acid on bone mineralization density distribution at 6 and 24 months in the SHOTZ study. J Bone Miner Res. 2016;31(8):1527-1535. http://dx.doi.org/10.1002/jbmr.2825
Glossary
PMW = postmenopausal women
Date of Last Review: March 02, 2020
Contact Lilly
Call Us
If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.
Available Mon - Fri, 8am - 7pm ET
